A case of monoclonal immunoglobulin light- and heavy-chain deposition disease exhibiting atypical deposition with fibrillary structures, successfully treated with chemotherapy

Clinical Nephrology

Volumn 64, Issue 3, 2005, Pages 221-227

  Nakatsuka, A ^a   Maeshima, Y ^a   Sarai, A ^a   Yanai, H ^a   Sugiyama, H ^a   Yamasaki, Y ^a   Makino, H ^a  

^a OKAYAMA UNIVERSITY   (Japan)

Author keywords

Chemotherapy; Light and heavy chain deposition disease (LHCDD); Melphalan adn prednisolone (MP); Monoclonal immunoglobulin deposition disease (MIDD); Nodular glomerulosclerosis

Indexed keywords

CREATININE; IMMUNOGLOBULIN G; IMMUNOGLOBULIN HEAVY CHAIN; IMMUNOGLOBULIN LIGHT CHAIN; MELPHALAN; PARAPROTEIN; PREDNISONE;

ADULT; ARTICLE; BLOOD ANALYSIS; BONE MARROW BIOPSY; CASE REPORT; CHEMOTHERAPY; CREATININE BLOOD LEVEL; CREATININE CLEARANCE; DIAGNOSTIC ACCURACY; EARLY DIAGNOSIS; FEMALE; HISTOPATHOLOGY; HUMAN; IMMUNOGLOBULIN DEPOSITION; IMMUNOHISTOCHEMISTRY; KIDNEY BIOPSY; KIDNEY FAILURE; LIGHT AND HEAVY CHAIN DEPOSITION DISEASE; MONOCLONAL IMMUNOGLOBULIN DEPOSITION DISEASE; OUTCOMES RESEARCH; PROTEINURIA; SYSTEMIC DISEASE; URINALYSIS;

EID: 24644440525     PISSN: 03010430     EISSN: None     Source Type: Journal    
DOI: 10.5414/cnp64221     Document Type: Article

References (21)

1. Alpers CE, Biava CG 1989 Idiopathic lobular glomerulonephritis (nodular mesangial sclerosis): a distinct diagnostic entity. Clin Nephrol 32: 68-74
2. Bijol V, Silver SM, Nadasdy T 2002 A 65-year-old diabetic man with progressive renal insufficiency and proteinuria. Am J Kidney Dis 40: 429-434
3. Chang IJ, Cheunsuchon B, Miller FJ, Fogo AB 2003 A 66-year-old woman with progressive renal insufficiency, nephrotic syndrome, and monoclonal protein. Am J Kidney Dis 41: 508-517
4. Comenzo RL 2000 Hematopoietic cell transplantation for primary systemic amyloidosis: what have we learned? Leuk Lymphoma 37: 245-258
5. Gertz MA, Kyle RA 1990 Acute leukemia and cytogenetic abnormalities complicating melphalan treatment of primary systemic amyloidosis. Arch Intern Med 150: 629-633
6. Gertz MA, Lacy MQ, Dispenzien A 2002 Immunoglobulin light chain amyloidosis and the kidney. Kidney Int 61: 1-9
7. Gertz MA, Lacy MQ, Gastineau DA, Inwards DJ, Chen MG, Tefferi A, Kyle RA, Litzow MR 2000 Blood stem cell transplantation as therapy for primary systemic amyloidosis (AL). Bone Marrow Transplant 26: 963-969
8. Gertz MA, Lacy MQ, Lust JA, Greipp PR, Witzig TE, Kyle RA 1999 Prospective randomized trial of melphalan and prednisone versus vincristine, cannustine, melphalan, cyclophosphamide, and prednisone in the treatment of primary systemic amyloidosis. J Clin Oncol 17: 262-267
9. Heilman RL, Velosa JA, Holley KE, Offord KP, Kyle RA 1992 Long-term follow-up and response to chemotherapy in patients with light-chain deposition disease. Am J Kidney Dis 20: 34-41
10. Komatsuda A, Wakui H, Ohtani H, Kodama T, Miki K, Imai H, Miura AB 2000 Disappearance of nodular mesangial lesions in a patient with light chain nephropathy after long-term chemotherapy. Am J Kidney Dis 35: E9
11. Lin J, Markowitz GS, Valeri AM, Kambham N, Sherman WH, Appel GB, D'Agati VD 2001 Renal monoclonal immunoglobulin deposition disease: the disease spectrum. J Am Soc Nephrol 12: 1482-1492
12. Paueksakon P, Revelo MP, Horn RG, Shappell S, Fogo AB 2003 Monoclonal gammopathy: significance and possible causality in renal disease. Am J Kidney Dis 42: 87-95
13. Pozzi C, Fogazzi GB, Banfi G, Strom EH, Ponticelli C, Locatelli F 1995 Renal disease and patient survival in light chain deposition disease. Clin Nephrol 43: 281-287
14. Pozzi C, Locatelli F 2002 Kidney and liver involvement in monoclonal light chain disorders. Semin Nephrol 22: 319-330
15. Preud'homme JL, Aucouturier P, Touchard G, Striker L, Khamlichi AA, Rocca A, Denoroy L, Cogne M 1994 Monoclonal immunoglobulin deposition disease (Randall type). Relationship with structural abnormalities of immunoglobulin chains. Kidney Int 46: 965-972
16. Ronco PM, Alyanakian MA, Mougenot B, Aucouturier P 2001 Light chain deposition disease: a model of glomerulosclerosis defined at the molecular level. J Am Soc Nephrol 12: 1558-1565
17. Royer B, Arnulf B, Martinez F, Roy L, Flageul B, Etienne I, Ronco P, Brouet JC, Fermand JP 2004 High-dose chemotherapy in light chain or light and heavy chain deposition disease. Kidney Int 65: 642-648
18. Sanders PW, Herrera GA, Kirk KA, Old CW, Galla JH 1991 Spectrum of glomerular and tubulointerstitial renal lesions associated with monotypical immunoglobulin light chain deposition. Lab Invest 64: 527-537
19. Strom EH, Fogazzi GB, Banfi G, Pozzi C, Mihatsch MJ 1994 Light chain deposition disease of the kidney. Morphological aspects in 24 patients. Virchows Arch 425: 271-280
20. Wardley AM, Jayson GC, Goldsmith DJ, Venning MC, Ackrill P, Scarffe JH 1998 The treatment of nephrotic syndrome caused by primary (light chain) amyloid with vincristine, doxorubicin and dexamethasone. Br J Cancer 78: 774-776
21. Yamamoto Y, Maeshima Y, Kitayama H, Kitamura S, Takazawa Y, Sugiyama H, Yamasaki Y, Makino H 2004 Tumstatin Peptide, an inhibitor of angiogenesis, prevents glomerular hypertrophy in the early stage of diabetic nephropathy. Diabetes 53: 1831-1840